Linagliptin 2.5 mg Twice Daily Versus 5 mg Once Daily as add-on Therapy to Twice Daily Metformin in Type 2 Diabetes

PHASE2CompletedINTERVENTIONAL
Enrollment

491

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

September 30, 2010

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

linagliptin low dose

patient to receive tablets containing low dose linagliptin twice daily

DRUG

placebo

patient to receive placebo tablet(s) matching linagliptin

DRUG

linagliptin medium dose

patient to receive a tablet containing medium dose linagliptin once daily

Trial Locations (84)

Unknown

1218.62.32003 Boehringer Ingelheim Investigational Site, De Pinte

1218.62.32008 Boehringer Ingelheim Investigational Site, Kortenaken

1218.62.32009 Boehringer Ingelheim Investigational Site, Kumtich

1218.62.32005 Boehringer Ingelheim Investigational Site, Massemen-Wetteren

1218.62.32004 Boehringer Ingelheim Investigational Site, Natoye

1218.62.32007 Boehringer Ingelheim Investigational Site, Sint-Job-in't-Goor

1218.62.32002 Boehringer Ingelheim Investigational Site, Tessenderlo

1218.62.32006 Boehringer Ingelheim Investigational Site, Wilsele

1218.62.11012 Boehringer Ingelheim Investigational Site, Calgary

1218.62.11007 Boehringer Ingelheim Investigational Site, Burnaby

1218.62.11011 Boehringer Ingelheim Investigational Site, St. John's

1218.62.11006 Boehringer Ingelheim Investigational Site, Halifax

1218.62.11001 Boehringer Ingelheim Investigational Site, Barrie

1218.62.11003 Boehringer Ingelheim Investigational Site, Brampton

1218.62.11004 Boehringer Ingelheim Investigational Site, Markham

1218.62.11005 Boehringer Ingelheim Investigational Site, Sarnia

1218.62.11008 Boehringer Ingelheim Investigational Site, Smiths Falls

1218.62.11013 Boehringer Ingelheim Investigational Site, Strathroy

1218.62.11014 Boehringer Ingelheim Investigational Site, Toronto

1218.62.11010 Boehringer Ingelheim Investigational Site, Charlottetown

1218.62.11002 Boehringer Ingelheim Investigational Site, Montreal

1218.62.11009 Boehringer Ingelheim Investigational Site, Point Claire

1218.62.3303C Boehringer Ingelheim Investigational Site, Bort-les-Orgues

1218.62.3306A Boehringer Ingelheim Investigational Site, Bourg Des Cptes

1218.62.3303D Boehringer Ingelheim Investigational Site, Bugeat

1218.62.3302H Boehringer Ingelheim Investigational Site, Corsept

1218.62.3308A Boehringer Ingelheim Investigational Site, Derval

1218.62.3302B Boehringer Ingelheim Investigational Site, La Chapelle-sur-Erdre

1218.62.3304A Boehringer Ingelheim Investigational Site, Levallois-Perret

1218.62.3305A Boehringer Ingelheim Investigational Site, Marseille

1218.62.3305B Boehringer Ingelheim Investigational Site, Marseille

1218.62.3305G Boehringer Ingelheim Investigational Site, Marseille

1218.62.3305H Boehringer Ingelheim Investigational Site, Marseille

1218.62.3301A Boehringer Ingelheim Investigational Site, Nantes

1218.62.3302A Boehringer Ingelheim Investigational Site, Nantes

1218.62.3304B Boehringer Ingelheim Investigational Site, Paris

1218.62.3304D Boehringer Ingelheim Investigational Site, Paris

1218.62.3305F Boehringer Ingelheim Investigational Site, Roquevaire

1218.62.3305I Boehringer Ingelheim Investigational Site, Roquevaire

1218.62.3303A Boehringer Ingelheim Investigational Site, Rosiers-d'Égletons

1218.62.3303H Boehringer Ingelheim Investigational Site, Sainte-Fortunade

1218.62.3302I Boehringer Ingelheim Investigational Site, Sautron

1218.62.3302G Boehringer Ingelheim Investigational Site, Vue

1218.62.91001 Boehringer Ingelheim Investigational Site, Bangalore

1218.62.91004 Boehringer Ingelheim Investigational Site, Bangalore

1218.62.91003 Boehringer Ingelheim Investigational Site, Hyderabad, Andra Pradesh

1218.62.91005 Boehringer Ingelheim Investigational Site, Nagpru

1218.62.91002 Boehringer Ingelheim Investigational Site, Trivandrum

1218.62.39010 Boehringer Ingelheim Investigational Site, Ancona

1218.62.39006 Boehringer Ingelheim Investigational Site, Catania

1218.62.39004 Boehringer Ingelheim Investigational Site, Genova

1218.62.39009 Boehringer Ingelheim Investigational Site, Gissi (CH)

1218.62.39003 Boehringer Ingelheim Investigational Site, Palermo

1218.62.39001 Boehringer Ingelheim Investigational Site, Pisa

1218.62.39002 Boehringer Ingelheim Investigational Site, Pordenone

1218.62.39012 Boehringer Ingelheim Investigational Site, Ravenna

1218.62.39007 Boehringer Ingelheim Investigational Site, Roma

1218.62.39011 Boehringer Ingelheim Investigational Site, Roma

1218.62.60002 Boehringer Ingelheim Investigational Site, George Town

1218.62.60001 Boehringer Ingelheim Investigational Site, Kelantan Kota Bahru

1218.62.60005 Boehringer Ingelheim Investigational Site, Kuala Lumpur

1218.62.60003 Boehringer Ingelheim Investigational Site, Putrajaya

1218.62.60004 Boehringer Ingelheim Investigational Site, Seremban

1218.62.31007 Boehringer Ingelheim Investigational Site, Almere Stad

1218.62.31004 Boehringer Ingelheim Investigational Site, Breezerveld

1218.62.31005 Boehringer Ingelheim Investigational Site, Etten-Leur

1218.62.31002 Boehringer Ingelheim Investigational Site, Lieshout

1218.62.31001 Boehringer Ingelheim Investigational Site, Oude Pekela

1218.62.31008 Boehringer Ingelheim Investigational Site, Voerendaal

1218.62.31009 Boehringer Ingelheim Investigational Site, Wildervank

1218.62.31003 Boehringer Ingelheim Investigational Site, Woerden

1218.62.82005 Boehringer Ingelheim Investigational Site, Goyang

1218.62.82006 Boehringer Ingelheim Investigational Site, Goyang

1218.62.82003 Boehringer Ingelheim Investigational Site, Incheon

1218.62.82004 Boehringer Ingelheim Investigational Site, Pucheon

1218.62.82002 Boehringer Ingelheim Investigational Site, Seoul

1218.62.82001 Boehringer Ingelheim Investigational Site, Suwon

1218.62.34003 Boehringer Ingelheim Investigational Site, Badia Del Vallés (Barcelona)

1218.62.34002 Boehringer Ingelheim Investigational Site, L'Hospitalet de Llobregat (Barcelona)

1218.62.34005 Boehringer Ingelheim Investigational Site, Madrid

1218.62.34006 Boehringer Ingelheim Investigational Site, Madrid

1218.62.34007 Boehringer Ingelheim Investigational Site, Madrid

1218.62.34001 Boehringer Ingelheim Investigational Site, Palma (Mallorca)

1218.62.34008 Boehringer Ingelheim Investigational Site, Palma de Mallorca

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT01012037 - Linagliptin 2.5 mg Twice Daily Versus 5 mg Once Daily as add-on Therapy to Twice Daily Metformin in Type 2 Diabetes | Biotech Hunter | Biotech Hunter